Eclipsebio Acquires Terrain Bio — Assembles RNA Design‑to‑Manufacturing Stack

Eclipsebio acquired Terrain Bio to combine Terrain’s machine‑learning RNA design capabilities with Eclipsebio’s sequencing‑first analytics, aiming to build an end‑to‑end RNA therapeutic design, manufacturing and validation platform. The deal—terms undisclosed—was presented as strategic vertical integration to speed iterative RNA design and quality‑by‑design manufacturing decisions, a capability RNA drug developers increasingly demand as mRNA and saRNA assets push toward clinical and commercial scale.